In patients with advanced-stage classic Hodgkin lymphoma, a PFS benefit was seen at 3 years’ follow-up with N-AVD compared to BV-AVD.

R-CHOP plus ibrutinib, followed by ibrutinib maintenance improved PFS in treatment-naive patients aged 65 years and younger with high-risk ABC DLBCL.

Standard-risk rel/ref multiple myeloma patients with benefit from earlier treatment with cilta-cel, rather than waiting for later lines of therapy.

Investigators analyzed IBD subtypes and their associated risks of radical prostatectomy complications among a cohort of patients with prostate cancer to fill a knowledge gap.

Investigators sought to examine the connection between a diagnosis of cancer within 12 months following a diagnosis of hiccups ...

In this study, researchers investigated long-term outcomes from a real-world cohort of patients with stage IV melanoma treated with pembrolizumab following progression on prior therapies.

Researchers sought to determine whether adding fixed-duration venetoclax to RBAC in the first line would be effective in older patients with high-risk MCL.

Pemigatinib was well-tolerated among patients with CCA regardless of presence of CUP, but HCRU costs were higher with CUP vs without CUP.

FZOCUS-1 assessed the safety and efficacy of fuzuloparib alone and in combination with apatinib for patients with newly diagnosed or advanced ovarian cancer.

Perioperative chemotherapy is recommended for patients with cT2-4 and/or N+ resectable gastric cancer, preferably 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT).

A review of EMR data from younger and older women with breast cancer noted that social support was not consistently documented among patients.

In this retrospective cohort study, researchers investigated the association between travel time and mortality in prostate cancer patients.